Physician profile
Brian A Feagins
NPI 1649229790
$6,999.22
in general payments reported to CMS, 2019-2025
38 companies · $26.76 in 2025
The $26.76 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,013 · 2020: $726 · 2021: $1,492 · 2022: $2,413 · 2023: $840 · 2024: $489 · 2025: $26.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,355.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Valencia Technologies Corporation | $1,131.01 | 2022-2023 | Ecoin Device Kit |
| Caldera Medical, INC | $899.33 | 2021-2024 | Desara |
| Medtronic, INC. | $861.17 | 2021-2024 | Interstim |
| Medtronic USA, INC. | $793.91 | 2019-2020 | |
| Astellas Pharma US INC | $689.84 | 2019-2023 | Myrbetriq |
| Axonics, INC. | $485.00 | 2020-2023 | Axonics, Bulkamid |
| Boston Scientific Corporation | $282.41 | 2019-2024 | Ams 800 Artificial Urinary Sphincter |
| Coloplast Corp | $159.10 | 2019-2023 | Titan |
| Antares Pharma, INC. | $145.64 | 2019-2021 | |
| Abbvie INC. | $141.26 | 2022-2024 | |
| Myovant Sciences INC. | $133.67 | 2021-2022 | |
| Therapeuticsmd, INC. | $129.31 | 2019 | |
| Urogen Pharma, INC. | $120.68 | 2022 | |
| Pfizer INC. | $101.66 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $96.58 | 2023-2024 | Gemtesa |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acerus Pharmaceuticals Corporation | $93.86 | 2020-2022 | |
| Urovant Sciences INC | $79.10 | 2022 | |
| Ferring Pharmaceuticals INC. | $72.04 | 2019 | |
| Innovation Technologies INC | $70.24 | 2022-2024 | Irrisept |
| Biotissue Holdings INC. | $56.13 | 2022 | |
| Janssen Biotech, INC. | $55.82 | 2019-2025 | Erleada |
| Merck Sharp & Dohme LLC | $43.14 | 2021-2023 | Lynparza, Keytruda |
| Endo Pharmaceuticals INC. | $41.79 | 2022-2023 | Aveed, Xiaflex |
| Olympus America INC. | $36.84 | 2023-2024 | Itind System |
| Cumberland Pharmaceuticals, INC. | $32.73 | 2022 | |
| Duchesnay USA Incorporated | $30.32 | 2019 | |
| Teleflex LLC | $24.59 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.39 | 2022 | |
| Allergan, INC. | $24.30 | 2019-2020 | |
| Aytu Biopharma, INC. | $20.51 | 2019 | |
| Sun Pharmaceutical Industries INC. | $19.40 | 2019 | |
| Millicent US INC | $18.92 | 2021 | |
| Procept Biorobotics Corporation | $15.55 | 2021 | |
| Dendreon Pharmaceuticals LLC | $15.16 | 2019 | |
| Verity Pharmaceuticals INC. | $14.88 | 2023 | Trelstar |
| Tolmar, INC. | $14.07 | 2023 | |
| Mission Pharmacal Company | $13.24 | 2019 | |
| Amgen INC. | $11.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Feagins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.